BioSpace News Archive

Cibus, a leading agricultural biotechnology company, announced the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer.

Gennao Bio, a privately-held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced new preclinical data for its gene monoclonal antibody (GMAB) platform technology was presented as a virtual poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

The global Recombinant Human Endostatin market report is an-depth study of drivers, trends, and economic forecast.

The increasing use of mesenchymal stem cells for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market.

Healthcare payer services are services that are outsourced by healthcare insurance payers and providers.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per a recent market analysis by Fact.MR, the global foot orthotic insoles market is projected to expand at a healthy 7.2% CAGR between 2020 and 2030.

Orphazyme A/S has introduced a modified long-term incentive program for 2021 with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the Company’s shareholders.

The Xlife-project company inflamed pharma GmbH has concluded an exclusive license agreement with the Austrian Vitesse Trading GmbH for the sale of its active ingredient ProcCluster.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced it has successfully completed the first ever heterotopic implant of its bioengineered liver transplant into a large animal.

CytoDyn Inc. announced today the filing of a complaint for declaratory and injunctive relief and motion for a preliminary injunction against NSF International, Inc. and its subsidiary Amarex Clinical Research (“Amarex”), the Company’s former Contract Research Organization (“CRO”).